Clinical Trial Update: Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluating donor T cells with low-dose aldesleukin and low-dose GM-CSF after donor stem cell transplant for relapsed or refractory non-Hodgki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Leukine (sargramostim)
• Proleukin (aldesleukin)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Lymphoma | Phase 1 | Status: WITHDRAWN